Perspective Therapeutics Inc
CATX2.865USD
+0.115+4.18%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
212.98MMarket Cap
LossP/E TTM
More Details of Perspective Therapeutics Inc Company
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Perspective Therapeutics Inc Info
Ticker SymbolCATX
Company namePerspective Therapeutics Inc
IPO dateMay 31, 2002
CEOSpoor (Johan M)
Number of employees138
Security typeOrdinary Share
Fiscal year-endMay 31
Address2401 Elliott Avenue
CitySEATTLE
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code98121
Phone12066760900
Websitehttps://www.perspectivetherapeutics.com/
Ticker SymbolCATX
IPO dateMay 31, 2002
CEOSpoor (Johan M)
Company Executives of Perspective Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Markus Puhlmann, M.D.
Dr. Markus Puhlmann, M.D.
Chief Medical Officer
Chief Medical Officer
137.54K
--
Mr. Johan M. (Thijs) Spoor
Mr. Johan M. (Thijs) Spoor
Chief Executive Officer, Director
Chief Executive Officer, Director
87.68K
+72.66%
Mr. Jonathan Robert Hunt
Mr. Jonathan Robert Hunt
Chief Accounting Officer
Chief Accounting Officer
59.80K
+22.54%
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
25.98K
--
Mr. Joel D. Sendek
Mr. Joel D. Sendek
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Frank Morich, M.D., Ph.D.
Dr. Frank Morich, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert Froman Williamson, III
Mr. Robert Froman Williamson, III
Independent Director
Independent Director
--
--
Ms. Lori A. Woods
Ms. Lori A. Woods
Chairman of the Board
Chairman of the Board
--
--
Ms. Maya Martinez-Davis
Ms. Maya Martinez-Davis
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Markus Puhlmann, M.D.
Dr. Markus Puhlmann, M.D.
Chief Medical Officer
Chief Medical Officer
137.54K
--
Mr. Johan M. (Thijs) Spoor
Mr. Johan M. (Thijs) Spoor
Chief Executive Officer, Director
Chief Executive Officer, Director
87.68K
+72.66%
Mr. Jonathan Robert Hunt
Mr. Jonathan Robert Hunt
Chief Accounting Officer
Chief Accounting Officer
59.80K
+22.54%
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
25.98K
--
Mr. Joel D. Sendek
Mr. Joel D. Sendek
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Frank Morich, M.D., Ph.D.
Dr. Frank Morich, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
290.00K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lantheus Holdings, Inc.
15.71%
Fidelity Management & Research Company LLC
7.77%
Fidelity Institutional Asset Management
5.70%
BlackRock Institutional Trust Company, N.A.
5.40%
The Vanguard Group, Inc.
4.62%
Other
60.80%
Shareholders
Shareholders
Proportion
Lantheus Holdings, Inc.
15.71%
Fidelity Management & Research Company LLC
7.77%
Fidelity Institutional Asset Management
5.70%
BlackRock Institutional Trust Company, N.A.
5.40%
The Vanguard Group, Inc.
4.62%
Other
60.80%
Shareholder Types
Shareholders
Proportion
Investment Advisor
33.67%
Corporation
15.71%
Hedge Fund
11.63%
Research Firm
6.15%
Investment Advisor/Hedge Fund
5.75%
Bank and Trust
1.41%
Individual Investor
0.88%
Private Equity
0.47%
Venture Capital
0.08%
Other
24.24%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
302
43.90M
83.07%
+614.00
2025Q3
305
43.90M
83.07%
+291.80K
2025Q2
297
43.61M
76.82%
-1.78M
2025Q1
297
46.15M
78.78%
-12.19M
2024Q4
284
48.39M
81.50%
-6.56M
2024Q3
258
49.52M
60.47%
+10.45M
2024Q2
207
38.90M
40.26%
+11.96M
2024Q1
134
24.95M
7.31%
+20.66M
2023Q4
87
4.23M
16.05%
+5.34K
2023Q3
89
4.23M
14.74%
+361.56K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lantheus Holdings, Inc.
11.68M
15.72%
--
--
Apr 02, 2025
Fidelity Management & Research Company LLC
6.76M
9.1%
-1.10M
-13.97%
Jun 30, 2025
Fidelity Institutional Asset Management
4.34M
5.85%
+2.15M
+97.90%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.94M
5.3%
+241.97K
+6.55%
Jun 30, 2025
The Vanguard Group, Inc.
3.27M
4.41%
+207.28K
+6.76%
Jun 30, 2025
Avidity Partners Management LP
1.86M
2.5%
-338.67K
-15.41%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.49M
2%
+14.18K
+0.96%
Jun 30, 2025
Millennium Management LLC
2.59M
3.49%
+2.49M
+2301.77%
Jun 30, 2025
Nicholson Wealth Management Group, LLC
1.61M
2.17%
+5.00K
+0.31%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.38M
1.86%
+188.89K
+15.82%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Fidelity Fundamental Small-Mid Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Biotechnology ETF
0.01%
Global X Russell 2000 ETF
0.01%
Schwab U.S. Broad Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Schwab U.S. Small-Cap ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
Fidelity Fundamental Small-Mid Cap ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Schwab U.S. Broad Market ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 09, 2024
Merger
10→1
Apr 09, 2024
Merger
10→1
Apr 09, 2024
Merger
10→1
Apr 09, 2024
Merger
10→1
Date
Type
Ratio
Apr 09, 2024
Merger
10→1
Apr 09, 2024
Merger
10→1
Apr 09, 2024
Merger
10→1
Apr 09, 2024
Merger
10→1
FAQs
Who are the top five shareholders of Perspective Therapeutics Inc?
The top five shareholders of Perspective Therapeutics Inc are:
Lantheus Holdings, Inc. holds 11.68M shares, accounting for 15.72% of the total shares.
Fidelity Management & Research Company LLC holds 6.76M shares, accounting for 9.10% of the total shares.
Fidelity Institutional Asset Management holds 4.34M shares, accounting for 5.85% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.94M shares, accounting for 5.30% of the total shares.
The Vanguard Group, Inc. holds 3.27M shares, accounting for 4.41% of the total shares.
Lantheus Holdings, Inc. holds 11.68M shares, accounting for 15.72% of the total shares.
Fidelity Management & Research Company LLC holds 6.76M shares, accounting for 9.10% of the total shares.
Fidelity Institutional Asset Management holds 4.34M shares, accounting for 5.85% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.94M shares, accounting for 5.30% of the total shares.
The Vanguard Group, Inc. holds 3.27M shares, accounting for 4.41% of the total shares.
What are the top three shareholder types of Perspective Therapeutics Inc?
The top three shareholder types of Perspective Therapeutics Inc are:
Lantheus Holdings, Inc.
Fidelity Management & Research Company LLC
Fidelity Institutional Asset Management
Lantheus Holdings, Inc.
Fidelity Management & Research Company LLC
Fidelity Institutional Asset Management
How many institutions hold shares of Perspective Therapeutics Inc (CATX)?
As of 2025Q4, 302 institutions hold shares of Perspective Therapeutics Inc, with a combined market value of approximately 43.90M, accounting for 83.07% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.00%.
What is the biggest source of revenue for Perspective Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Perspective Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
